Home » Newsletters » BioWorld Science

BioWorld Science

April 13, 2006

View Archived Issues

Snapshots of histone deacetylases (HDACs) as novel effective targets in cancer therapy: Part I

Galenea to focus on development of drugs to treat CNS diseases

DOR advances mucosal vaccine for botulinum toxin

PPARgamma agonists in cancer highlighted at AACR

Dosing completed in phase I study of Sinovac's H5N1 vaccine

Promising results seen with denosumab in postmenopausal osteoporosis

STRIDE studies reveal effects of sitaxsentan in pulmonary arterial hypertension

MPC-7869 beneficial in patients with mild, but not moderate, Alzheimer's disease

MBP-8298 delays multiple sclerosis progression

XP-13512 significantly improves restless legs syndrome

Garenoxacin effective in community-acquired pneumonia caused by resistant strains

Enrollment ahead of schedule in phase III study of VP-4896 for Alzheimer's

ProMetic begins enrollment in phase Ib/II study of PBI-1402

AlphaRx grants Proprius rights to Indaflex

Emisphere expands enrollment in phase II oral insulin trial

Phase II study of Aridol for COPD completes enrollment

Myriad Genetics and Abbott establish broad drug discovery collaboration

Schering-Plough selects compound from Pharmacopeia collaboration

Tostrex completes European MRP

Expansion of Biolex's collaboration with Medarex

Affymax studies Hematide in pure red cell aplasia patients

Amigal recommended for European orphan drug status for Fabry's disease

Preclinical update on ARRY-142886

Small-molecule pan-ErbB inhibitor selected by J&J as development candidate

Novel analgesic agents reported in recent patents

New AIDS diagnostic developed by Bio-Rad Pasteur

Recent patents describe novel agents for neurological disorders

mTOR inhibitor from Biotica shows potential for glioblastoma multiforme

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...